SCHEMBL25037086

SCHEMBL25037086

CCc1c(N2CCN(C(=O)OC(C)(C)C)CC2)c(=O)n2nc(C3=CCOCC3)nc2n1CC(=O)Nc1ccc(Cl)cc1Cl

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ WRN Q14191 1/20 0.65
▸ DPP4 P27487 1/20 0.35
▸ MEN1 O00255 4/20 0.35
▸ KMT2A Q03164 4/20 0.35
▸ POLB P06746 1/20 0.34
▸ ALDH1A1 P00352 3/20 0.33
▸ ATM Q13315 1/20 0.33
▸ MAPK8 P45983 1/20 0.33
▸ TBK1 Q9UHD2 1/20 0.33
▸ NOD2 Q9HC29 1/20 0.33
▸ NOD1 Q9Y239 1/20 0.33
▸ KDM4E B2RXH2 1/20 0.32
▸ HPGD P15428 1/20 0.32
▸ HTT P42858 1/20 0.32
▸ SMN1; SMN2 Q16637 1/20 0.32
▸ NPSR1 Q6W5P4 1/20 0.32
▸ P2RX7 Q99572 1/20 0.32
▸ CNR1 P21554 1/20 0.32
▸ CNR2 P34972 1/20 0.32
▸ MAPT P10636 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30038334 1.00 WRN (0.65) WRNDPP4MEN1KMT2APOLB
SCHEMBL25037129 0.94 WRN (0.64) WRNALDH1A1MAPK8TBK1NOD2
SCHEMBL30037529 0.94 WRN (0.64) WRNALDH1A1MAPK8TBK1NOD2
SCHEMBL25035161 0.93 WRN (0.75) WRNPOLBALDH1A1MAPK8TBK1
SCHEMBL30038230 0.93 WRN (0.75) WRNPOLBALDH1A1MAPK8TBK1
SCHEMBL25037168 0.92 WRN (0.63) WRNALDH1A1MAPK8TBK1NOD2
SCHEMBL31394096 0.91 WRN (0.64) WRNMAPK8TBK1NOD2NOD1
SCHEMBL31394474 0.91 WRN (0.72) WRNMEN1KMT2APOLBALDH1A1
SCHEMBL30037962 0.91 WRN (0.60) WRNMAPK8TBK1NOD2NOD1
SCHEMBL30984269 0.90 WRN (0.64) WRNPOLBMAPK8TBK1NOD2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230046859-A1 Bicyclic Compounds and their Uses NOVARTIS PHARMA AG (CH) 2023-02-16 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230046859-A1 Bicyclic Compounds and their Uses H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, C1R, F12 WRN 1829/4885DPP4 3644/4885MEN1 938/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback